"New Ocular Health Supplement Targets Glaucoma" - Nancy Hemphill
Guardion Health Sciences Inc. announced the launch of GlaucoCetin, a propriety formula shown in a clinical trial to reverse mitochondrial dysfunction in the optic nerve cells of glaucoma patients. GlaucoCetin is an enhanced version of the parent compound, GlaucoHealth, which was created by Robert Ritch, MD, clinical professor of ophthalmology at the Icahn School of Medicine at Mount Sinai. According to Dr. Ritch, “Formulations with IOP-independent neuroprotective effects could be additive in slowing progression rates by reversing mitochondrial dysfunction.” He added, “Stabilizing mitochondria could shift the treatment paradigm to an earlier stage of disease, prior to retinal ganglion cell death.”
— Robert Ritch, MD, Clinical Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Chief, Glaucoma Services, New York Eye and Ear Infirmary of Mount Sinai
Blinding Eye Disease Strongly Associated With Serious Forms of Cardiovascular Disease
Nov 17, 2022 View All Press Releases
High-Tech Imaging Offers New Way to Detect Signs of Early Glaucoma
Aug 02, 2022 View All Press Releases
Blinding Eye Disease Is Strongly Associated With Heart Disease and Stroke
Jul 12, 2022 View All Press ReleasesThree Mount Sinai Ophthalmologists Receive Prestigious Achievement Awards
Dec 01, 2020 View All Press Releases